TABLE 2

Trends in most common drug targets

This table illustrates the top 20 targets for drugs other than vaccines and advanced biologicals, like CAR T cells. Note, proteins binding with the Fc region of antibodies have been removed from the table. The presence is calculated by the number of trials in which a particular target has been drugged. If a single trial contains more than one agent that targets a particular drug target, this trial is counted as the number of these agents. Max phase column illustrates the maximal phase of a clinical trial in which a particular target has appeared. Trials with phase four have not been included because of the fact they contain agents that were never approved for brain tumors, and likely their phase is not equal for all analyzed treatment arms. Approved drug targets are labeled as approved. The number of clinical trials is calculated by the number of trials in which a particular target has been drugged, and each trial is counted only once, no matter the number of agents against the target. The number of unique drugs illustrates the number of drugs that exploit the target. For each drug, both pivotal and secondary targets were taken into account. The trend was calculated as follows: if a 3-year avg. of the target presence during 2017, 2018, and 2019 is 10% or more higher than the avg. during the 10-year period, the trend is upward, whereas if it is 10% or more below than the avg. during the 10-year period, the trend is downward. The year column illustrates the first year the target appeared during the analyzed 10 years of brain cancer trials. Data are to February 2020.